Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pro-Pharmaceuticals has entered into a new research collaboration with Mount Sinai School of Medicine to evaluate in pre-clinical models, the anti-fibrotic effects of several of the company's novel, Galectin-targeting compounds.
Subscribe to our email newsletter
Pro-Pharmaceuticals said that in previous experiments its polysaccharide compounds that target Galectin receptors have been shown to reverse the formation of fibrotic tissue in diseased rat livers.
Scott Friedman from Mount Sinai School of Medicine will be testing several of the company’s galactomannans and-rhamnogalacturonans as Galectin blockers in liver anti-fibrotic therapies.
Pro-Pharma chief medical officer Peter Traber said that collaborating with Mount Sinai represents an exciting opportunity to partner with a premier liver research program to develop a novel method for treating liver disease.
"We believe our expertise in developing compounds that target Galectin receptors offers opportunities to develop new paradigms for the treatment of cancer, fibrosis and inflammatory diseases," Traber said.